Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- JSMI Announces Vision for Activation of OTC Drug Industry
June 1, 2009
- Suzuken: Sharp Fall in Profits Despite 3.4% Increase in Sales
June 1, 2009
- Meiji HD: Generics Bolster Pharma Business
June 1, 2009
- Reform of Profit Structure "Task of Pressing Urgency": Mr Kumakura
June 1, 2009
- Toho: Operating Profit Rate Down to 0.36%
June 1, 2009
- Asahi Kasei Pharma: License Fee for Famvir Boost Sales 13.1%
June 1, 2009
- Overseas Sales of Top-Eight Companies Up to 43.1% of Total Sales
June 1, 2009
- Yakult Honsha: Elplat Props Up Business
June 1, 2009
- Taisho: Sales Up 2.6% with Addition of Biofermin
June 1, 2009
- SymBio Licenses Bendamustine to Eisai in South Korea, Singapore
June 1, 2009
- Kyorin: Sales Up 12.1% Driven by Kipres, Pentasa
June 1, 2009
- Companies Take Strict Measures to Prevent Flu Infections
June 1, 2009
- Kaken: Profits Up for the 7th Year Running
June 1, 2009
- BUSINESS NEWS IN BRIEF
June 1, 2009
- Mochida: Epadel, Atelec Drive Sales
June 1, 2009
- REGULATORY NEWS IN BRIEF
June 1, 2009
- Kissei: Urief, Glufast Drive Business
June 1, 2009
- PIII Trial of Amitiza for CIC Initiated in Japan: Sucampo, Abbott
June 1, 2009
- Nippon Shinyaku: Eviprostat, Intellectual Properties Bolster Business
June 1, 2009
- R&D NEWS IN BRIEF
June 1, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…